Gelteq Limited is a micro-cap pharma stock in a difficult place this week: the price has fallen 23% in five days to $0.43, and short interest has simultaneously snapped back toward the highs it set in early April, creating a setup where selling pressure and bearish positioning are reinforcing each other.
The positioning picture is the most striking thing about GELS right now. Short interest as a percentage of the free float jumped to 1.72% on May 12 — more than doubling in a single session from 0.69% on May 11. That spike erases the reset that had occurred through late April, when shorts had pulled back to roughly 1.03% of float after peaking near 2.3% in early April. The ORTEX short score reflects the shift: it moved from around 56 earlier in the week to 63.1 on May 12, its highest reading in the recent history covered here. The direction is clear — short sellers are re-entering a stock that has already lost 38% over the past month.
The borrow market tells a more nuanced story. Cost to borrow is still expensive at 106%, but that is actually down from the mid-March peak above 160% and the early April peak near 148%. Borrow availability is running at roughly 160% of estimated short interest, which points to reasonable lending supply — there are still shares available to locate. That level of availability means the fresh short-building this week is not being constrained by the borrow market; rather, shorts are stepping in with relative ease despite the elevated cost.
Ownership is tightly concentrated in a handful of founding-adjacent shareholders. The top three holders — ACK Pty Ltd., David Golik, and FF Okram Pty Ltd. — collectively hold just over 32% of shares. Nathan Givoni and Simon Szewach each added to their positions as recently as March, with Givoni adding 92,449 shares and Szewach adding 184,897 shares at that filing. Bradley Karp built a fresh 500,000-share position in the same March filing period. That insider-cluster buying in March now sits underwater by a significant margin given the subsequent decline, which adds an element of watch-and-wait for anyone tracking whether those buyers step back in.
Post-earnings price reactions have been inconsistent, making it hard to read a pattern. The March 2026 print produced a 6.5% gain on the day. The November 2025 event that drew the most attention was a 23.8% single-day rally with an 18.1% follow-through over five days. More recent reports, however, produced muted or slightly negative reactions. No next earnings date is currently on the calendar.
With no scheduled catalyst visible, the focus for GELS will be whether the short-side re-entry seen on May 12 is confirmed in subsequent sessions, and whether the founding-adjacent buyers from March choose to defend the stock at current levels near $0.43.
See the live data behind this article on ORTEX.
Open GELS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
